8-K: BioCardia's CardiAMP Trial Shows Strong Angina Reduction

BioCardia announced positive primary endpoint results from its CardiAMP Cell Therapy trial for chronic myocardial ischemia, showing improved exercise tolerance and reduced angina.

Summary

• The open-label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial demonstrated positive primary endpoint results.
• The minimally-invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events.
• Patients experienced an average increase of 80 seconds in exercise tolerance.
• An average of 82% reduction in angina episodes was observed at the six-month primary endpoint when compared to pre-treatment measurements.
• Sixty percent of the patients showed substantial improvements in both exercise tolerance and angina reduction.
• These early, open-label results compare favorably to those demonstrated by current FDA approved therapies such as Ranolazine and Enhanced External Counter Pulsation (EECP).
• Patients already on Ranolazine experienced dramatic reduction in angina episodes at the six-month follow-up.

Sentiment

Score: 8

Explanation: The results are highly positive, showing significant improvements in key endpoints (exercise tolerance, angina reduction) with good tolerability. The comparison to existing FDA-approved therapies is favorable, and the therapy addresses a significant unmet medical need. The 'Breakthrough Therapy' designation also adds to the positive sentiment. The only slight dampener is the investigational status and general risks associated with clinical development and funding.

Positives

• The CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events.
• All patients on guideline-directed medical therapy (GDMT) responded positively to the autologous cell therapy.
• Patients showed an average increase of 80 seconds in exercise tolerance.
• Patients experienced an average of 82% reduction in angina episodes at the six-month primary endpoint.
• Sixty percent of patients achieved substantial improvements in both exercise tolerance and angina reduction.
• The results compare favorably to existing FDA-approved therapies such as Ranolazine and EECP.
• The therapy addresses a significant unmet need for 600,000 to 1.8 million patients in the United States suffering from chronic myocardial ischemia with refractory angina.
• CardiAMP Cell Therapy has received FDA Breakthrough Therapy designation for Ischemic Heart Failure.
• The CardiAMP cell therapy trials are covered by the Center for Medicare and Medicaid for both treatment and control procedures.

Risks

• The continued development and cost of BioCardia's autologous cell-based therapies.
• The probability of success of the CardiAMP clinical trials.
• The ability to offset clinical costs utilizing Medicare reimbursement.
• The ultimate success of clinical cell therapy programs.
• The Company's liquidity position and its ability to raise additional funds.
• The Company's ability to successfully advance its clinical trials.
• Actual results may differ materially from forward-looking statements due to various factors.

Future Outlook

The company plans to submit the roll-in cohort results for peer-reviewed scientific publication. These results support the continued development of this novel therapeutic approach for chronic myocardial ischemia with refractory angina and enhance the value of the CardiAMP cell therapy platform. The therapy is currently limited by United States law to investigational use.

Management Comments

• "With these final roll-in results, this novel investigational therapy shows promise in addressing debilitating refractory angina, a significant unmet need for patients with chronic myocardial ischemia." Carl Pepine, MD, MACC, Professor of Medicine, Division of Cardiovascular Medicine, University of Florida at Gainesville.
• "We are working with our investigators to submit these results for peer reviewed scientific publication." Peter Altman, President and CEO.
• "The results from this roll-in cohort supports our continued development of this novel therapeutic approach for chronic myocardial ischemia with refractory angina and enhances the value of our CardiAMP cell therapy platform." Peter Altman, President and CEO.

Industry Context

The positive results for CardiAMP Cell Therapy address a significant unmet medical need for patients with chronic myocardial ischemia and refractory angina, a condition affecting an estimated 600,000 to 1.8 million patients in the US. This positions BioCardia as a potential innovator in the cardiovascular therapeutics space, particularly for patients who are suboptimal candidates for conventional revascularization. The therapy's favorable comparison to existing FDA-approved treatments like Ranolazine and EECP suggests a competitive edge in efficacy for this challenging patient population.

Comparison to Industry Standards

• The observed improvements in exercise tolerance (average 80 seconds increase) and angina reduction (average 82%) compare favorably to current FDA approved therapies.
• Specifically, the results are noted to be better than or comparable to those demonstrated by Ranolazine (e.g., ERICA and CARISA trials) and Enhanced External Counter Pulsation (EECP) (e.g., MUST-EECP study), which are established treatments for angina.
• The results are also in line with previous compelling investigational trial results utilizing cost prohibitive cell therapy, suggesting a potentially more accessible or efficient approach.

Stakeholder Impact

• Shareholders: Positive clinical trial results could increase investor confidence and potentially lead to stock price appreciation, especially given the unmet medical need and favorable comparisons to existing therapies.
• Patients: The therapy offers a promising new treatment option for patients with chronic myocardial ischemia and refractory angina, a debilitating condition with limited effective treatments.
• Medical Community: The results, once peer-reviewed, could influence treatment guidelines and clinical practice for refractory angina.
• Regulatory Bodies (FDA, CMS): Continued positive data supports the ongoing investigational use and potential future approval, with current Medicare/Medicaid coverage for trials being a positive.

Next Steps

• Submission of the roll-in cohort results for peer-reviewed scientific publication.
• Continued development of the CardiAMP therapeutic approach for chronic myocardial ischemia with refractory angina.

Key Dates

Recommendation

The positive top-line data from the CardiAMP Cell Therapy trial's roll-in cohort demonstrates significant improvements in exercise tolerance and a substantial reduction in angina episodes, comparing favorably to existing FDA-approved therapies. This addresses a large unmet medical need and, combined with the FDA Breakthrough Therapy designation, positions BioCardia for strong future growth potential. While risks associated with clinical development and funding exist, the compelling early efficacy and safety profile warrant a strong buy recommendation for long-term investors.

Keywords

BioCardia, BCDA, CardiAMP, Cell Therapy, Chronic Myocardial Ischemia, Refractory Angina, Cardiovascular Disease, Clinical Trial, Biotechnology, Autologous Cell Therapy, FDA Breakthrough Therapy